ACCESS Newswire
22 Nov 2022, 18:01 GMT+10
MINNEAPOLIS, MN / ACCESSWIRE / November 22, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for cancer treatment, today announced that an abstract accepted for a Spotlight Poster presentation at the 2022 San Antonio Breast Cancer Symposium (SABCS) is now available on the SABCS website. The 2022 San Antonio Breast Cancer Symposium (SABCS) is being held virtually and in-person from December 6-10, 2022.
The presentation will include updated efficacy and safety data and sub-group analysis by PIK3CA mutation status in the four expansion arms of a Phase 1b study of gedatolisib (a dual PI3K/mTOR inhibitor) plus palbociclib (a CDK4/6 inhibitor) and endocrine therapy in women with hormone receptor positive advanced breast cancer. The primary endpoint was investigator assessed objective response rate (ORR). Secondary endpoints included safety, duration of response and progression free survival (PFS). Promising ORR and PFS were seen in all arms, regardless of PIK3CA mutation status. Arm D, which treated patients whose disease progressed on a CDK4/6 inhibitor, reported ORR of 63% overall, 73% in PIK3CA-mutation patients, and 60% in PIK3CA-wild type patients; overall PFS was 12.9 months. Arm A, which evaluated patients who were treatment-naïve in the advanced disease setting, reported ORR of 85% overall, 81% in PIK3CA-wild type patients, and 100% in PIK3CA-mutations patients; median PFS was not reached after a median follow-up period of 33.1 months.
These preliminary findings demonstrate promising activity for gedatolisib plus palbociclib and endocrine therapy in patients who were CDK4/6 inhibitor-naïve and in those whose disease progressed on or after treatment with a CDK4/6 inhibitor, regardless of PIK3CAmutation status. Arm D results provide a strong rationale for Celcuity's Phase 3 clinical trial (VIKTORIA-1) in patients with advanced breast cancer whose disease progressed on or after CDK4/6 therapy. The encouraging results in treatment-naïve advanced breast cancer patients warrant further evaluation of gedatolisib in combination with a CDK4/6 inhibitor and endocrine therapy in early line settings, including front-line, neoadjuvant, or adjuvant indications.
Poster presentation details are provided below.
Poster Title: 'Updated results of a Phase 1b study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: Subgroup analysis by PIK3CA mutation status'
Author: Robert Wesolowski, et al.
Poster ID: PD13-05
Poster Session: Spotlight Poster Discussion Session 13
Presentation Time: December 8, 2022, 5 - 6:15 p.m. CT (6 - 7:15 p.m. ET)
Additional data will be presented at the Spotlight Poster Discussion, and the poster will be available on Celcuity's website after the poster is presented.
For more details about SABCS please visit: https://www.sabcs.org/.
About Celcuity
Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, reversible dual inhibitor that selectively targets all Class 1 PI3K isoforms and mTOR. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. The company has activated the Phase 3 VIKTORIA-1 clinical trial to evaluate gedatolisib in patients with HR+/HER2- advanced breast cancer. More detailed information about the VIKTORIA-1 study can be found at ClinicalTrials.gov. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at Celcuity.com. Follow us on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains statements that constitute 'forward-looking statements' including, but not limited to, the timing of enrolling patients in, and receiving results from, Celcuity's Phase 3 VIKTORIA-1 clinical trial, expectations with respect to potential results from such trial, and expectations for the efficacy and safety of gedatolisib. In some cases, you can identify forward-looking statements by terminology such as 'may,' 'should,' 'expects,' 'plans,' 'anticipates,' 'believes,' 'estimates,' 'predicts,' 'potential,' 'intends' or 'continue,' and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. Forward-looking statements are subject to numerous risks, uncertainties, and conditions, many of which are beyond the control of Celcuity. These include, but are not limited to, those risks set forth in the Risk Factors section in Celcuity's Quarterly Report for the period ended September 30, 2022 filed with the Securities and Exchange Commission on November 10, 2022. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Celcuity undertakes no obligation to update these statements for revisions or changes after the date of this press release, except as required by law
Contact:
Celcuity Inc.
Brian Sullivan, [email protected]
Vicky Hahne, [email protected]
(763) 392-0123
ICR Westwicke
Robert Uhl, [email protected]
(619) 228-5886
SOURCE: Celcuity Inc.
Get a daily dose of Atlanta Leader news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Atlanta Leader.
More InformationEVERGLADES, Florida: Over the weekend, a diverse coalition of environmental activists, Native American leaders, and residents gathered...
BEIJING, China: China's national soccer team may struggle to stir excitement, but its humanoid robots are drawing cheers — and not...
]LONDON, U.K.: A World Health Organization (WHO) expert group investigating the origins of the COVID-19 pandemic released its final...
DOVER, Delaware: California Governor Gavin Newsom has taken legal aim at Fox News, accusing the network of deliberately distorting...
FRANKFURT, Germany: Germany has become the latest country to challenge Chinese AI firm DeepSeek over its data practices, as pressure...
TORONTO, Canada: Harvard University and the University of Toronto have created a backup plan to ensure Harvard graduate students continue...
NEW YORK, New York - Global stock indices closed with divergent performances on Tuesday, as investors weighed corporate earnings, central...
TORONTO, Canada: Canadian Prime Minister Mark Carney announced late on June 29 that trade negotiations with the U.S. have recommenced...
Vancouver, Canada: A high-stakes legal showdown is brewing in the world of athleisure. Lululemon, the Canadian brand known for its...
LONDON, U.K.: British oil giant Shell has denied reports that it is in talks to acquire rival oil company BP. The Wall Street Journal...
NEW YORK, New York - U.S. stock markets closed firmly in positive territory to start the week Monday, with the S&P 500 and Dow Jones...
WASHINGTON, D.C.: On Friday, President Donald Trump announced that he was halting trade discussions with Canada due to its decision...